ArticleMolecular medicine (Cambridge, Mass.)2025
Secreted AZGP1 induced by 5-FU binds to PD-L1 and promotes apoptosis in cholangiocarcinoma.
Article in Molecular medicine (Cambridge, Mass.), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCholangiocarcinoma (CCA) is an aggressive malignancy with limited treatment options and poor clinical outcomes. The identification of predictive biomarkers that can enhance chemotherapy efficacy and inform immune modulation remains an urgent unmet need.
methodsWe investigated the biological role and regulatory mechanisms of soluble AZGP1 in CCA using western blotting, ELISA, flow cytometry, and in vitro/in vivo functional assays. A combination of pharmacological treatments and gene expression analyses was employed to explore pathway dynamics and immune responses.
resultsWe found that soluble AZGP1, which is typically downregulated in CCA, is significantly upregulated following 5-fluorouracil (5-FU) treatment. Mechanistically, 5-FU modulates the AKT–Foxo1 signaling pathway, promoting nuclear translocation of Foxo1 and activation of AZGP1. Elevated soluble AZGP1 levels were shown to interact with PD-L1, enhancing apoptosis in cancer cells. Analyses of peripheral blood mononuclear cells (PBMCs) further confirmed the immune-modulating potential of AZGP1 in the tumor microenvironment.
conclusionsOur findings reveal that soluble AZGP1 acts as a predictive biomarker for 5-FU efficacy in cholangiocarcinoma and exerts pro-apoptotic and immunomodulatory functions via interaction with PD-L1. These insights may contribute to the development of more precise and effective therapeutic strategies in CCA treatment.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.